Impact of haemoglobin and erythropoietin dose changes on mortality: A secondary analysis of results from a randomized anaemia management trial

Nephrology Dialysis Transplantation

Volumn 25, Issue 12, 2010, Pages 4002-4009

  Lau, Joanne H ^a   Gangji, Azim S ^a   Rabbat, Christian G ^a   Brimble, K Scott ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

anaemia; erythropoiesis stimulating agents; haemodialysis; haemoglobin variability; mortality

Indexed keywords

ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS GLUCONATE; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY ANALYSIS; TREATMENT OUTCOME;

AGED; ANEMIA, IRON-DEFICIENCY; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78649497302     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq330     Document Type: Article

References (39)

1. Ritz E, Laville M, Bilous RW et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007; 49: 194-207
2. Laupacis A, Wong C, Churchill D. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythro-poietin. The Canadian Erythropoietin Study Group. Control Clin Trials 1991; 12: 168S-179S
3. Beusterien KM, Nissenson AR, Port FK et al. The effects of recom-binant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996; 7: 763-773
4. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
5. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
6. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
7. Pfeffer MA, Burdmann EA, Chen CYet al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
8. Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381-388 9.
9. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798
10. Culleton BF, Manns BJ, Zhang J et al. Impact of anemia on hospitalization and mortality in older adults. Blood 2006; 107: 3841-3846
11. Zakai NA, Katz R, Hirsch C et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med 2005; 165: 2214-2220
12. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191
13. Brimble KS, McFarlane A, Winegard N et al. Effect of chronic kidney disease on red blood cell rheology. Clin Hemorheol Microcirc 2006; 34: 411-420
14. Scalera F, Kielstein JT, Martens-Lobenhoffer J et al. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 2005; 16: 892-898
15. Diaz-Ricart M, Etebanell E, Cases A et al. Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Thromb Haemost 1999; 82: 1312-1317
16. Fuste B, Serradell M, Escolar G et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88: 678-685
17. Brunelli SM, Lynch KE, Ankers ED et al. Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1733-1740
18. Brunelli SM, Joffe MM, Israni RK et al. History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 777-782
19. Yang W, Israni RK, Brunelli SM et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18: 3164-3170
20. Ebben JP, Gilbertson DT, Foley RN et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitali-zations. Clin J Am Soc Nephrol 2006; 1: 1205-1210
21. Gilbertson DT, Ebben JP, Foley RN et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008; 3: 133-138
22. Ishani A, Solid CA, Weinhandl ED et al. Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. Nephrol Dial Transplant 2008; 23: 1682-1689
23. Boudville NC, Djurdjev O, Macdougall IC et al. Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. Clin J Am Soc Nephrol 2009; 4: 1176-1182
24. Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol 2009; 20: 479-487
25. Brimble KS, Rabbat CG, McKenna P et al. Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial. J Am Soc Nephrol 2003; 14: 2654-2661
26. Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-1632
27. Gaweda AE, Jacobs AA, Aronoff GR et al. Model predictive control of erythropoietin administration in the anemia of ESRD. Am J Kidney Dis 2008; 51: 71-79
28. Zhang Y, Thamer M, Stefanik K et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876
29. Kilpatrick RD, Critchlow CW, Fishbane S et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077-1083
30. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembol-ism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-924
31. Yilmaz MI, Sonmez A, Saglam M et al. Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease. Kidney Int 2009; 75: 1316-1321
32. Chen HC, Tsai JC, Tsai JH et al. Recombinant human erythropoietin enhances superoxide production by FMLP-stimulated polymorpho-nuclear leukocytes in hemodialysis patients. Kidney Int 1997; 52: 1390-1394
33. Tassies D, Reverter JC, Cases A et al. Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: association with early improvement in platelet function. Am J Hematol 1998; 59: 105-109
34. West RM, Harris K, Gilthorpe MS et al. Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. J Am Soc Nephrol 2007; 18: 2371-2376
35. Fishbane S, Berns JS. Evidence and implications of haemoglobin cycling in anaemia management. Nephrol Dial Transplant 2007; 22: 2129-2132
36. Astor BC, Eustace JA, Powe NR et al. Type of vascular access and survival among incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. J Am Soc Nephrol 2005; 16: 1449-1455
37. Dhingra RK, Young EW, Hulbert-Shearon TE et al. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 2001; 60: 1443-1451
38. Polkinghorne KR, McDonald SP, Atkins RC et al. Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol 2004; 15: 477-486
39. Xue JL, Dahl D, Ebben JPet al. The association of initial hemodialysis access type with mortality outcomes in elderly Medicare ESRD patients. Am J Kidney Dis 2003; 42: 1013-1019